ArticleDrug design, development and therapy2026
Synergistic Enhancement of Diosgenin Dissolution and Bioavailability via Ternary Solid Dispersions and Self-Assembled Polymeric Micelles.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to optimize the dissolution properties of the poorly soluble drug diosgenin (Dio) using ternary solid dispersions (TSDs) to enhance its bioavailability. Additionally, we characterized the prepared diosgenin ternary solid dispersions (Dio-TSDs), and explored their potential solubilization mechanisms. Methods: Based on carrier screening and solubility evaluation, Soluplus was selected as the primary carrier and combined with either PVP VA64 or PEG 2000 to construct Dio ternary solid dispersions using the solvent method. The optimal formulation of Dio-TSDs was selected based on dissolution performance. Characterization, component interaction analysis, and stability assessment were performed using water contact angle measurements, differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), scanning electron microscopy (SEM), dynamic light scattering (DLS), transmission electron microscopy (TEM), Fourier-transform infrared spectroscopy (FT-IR), nuclear magnetic resonance (NMR), and molecular dynamics (MD). Pharmacokinetics was evaluated in Sprague-Dawley rats. Results: The Dio: Soluplus: PVP VA64 (10:63:27) -TSD (Dio-S-PVP-TSD) and Dio: Soluplus: PEG2000 (10:81:9) -TSD (Dio-S-PEG-TSD) improved Dio dissolution, reaching dissolution rates of 92.24% and 79.69%. Characterization results demonstrated that the carriers improved the wettability of Dio, and Dio was predominantly amorphous in the Dio-TSDs. Spherical-like nanomicelles were observed in aqueous solution. Interaction analysis revealed that non-covalent interactions facilitated the self-assembly of core-shell nanoclusters, with the polymer protecting Dio molecules in the core. Dio-S-PVP-TSD showed better physical stability during storage, whereas Dio-S-PEG-TSD showed a greater ability to maintain supersaturation. Both Dio-S-PVP-TSD and Dio-S-PEG-TSD demonstrated 5.49 and 6.15 times higher bioavailability than pure Dio in pharmacokinetic studies. Conclusion: Dio-S-PVP-TSD and Dio-S-PEG-TSD enhanced the dissolution and bioavailability of Dio, providing a promising strategy for improving the oral bioavailability of poorly soluble compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.